Long non-coding RNAs (lncRNAs) such as PCAT1..
2015 James Litinsky–PCF Young Investigator Award
University of Michigan
Arul Chinnaiyan, MD, PhD; Felix Feng, MD
Investigating Long Noncoding RNAs in Aggressive Prostate Cancer
Next generation sequencing (NGS) is a growing..
Rendong Yang, PhD:
University of Minnesota
Scott Dehm, PhD
Delineating Coding and Regulatory Indels in Prostate Cancer
Genomic analysis of cancer tissue has enabled..
Adam Sowalsky, PhD:
National Cancer Institute
Kathleen Kelly, PhD; William Dahut, MD
Investigations into the Mechanisms of Resistance to Enzalutamide in CRPC
As life expectancy rises, greater numbers of..
Prasanna Sooriakumaran, MBBS, PhD:
University of Oxford
Freddie C. Hamdy, MD
Improving Quality of Care for Men with Skeletal Metastases from Prostate Cancer: Defining the Burden-of-Treatment and its Management, and Developing Models to Predict Quality-of-Life
Cancer is characterized by accumulation and loss..
Shabnam Shalapour, PhD:
University of California, San Diego
Michael Karin, PhD
Development of Immunosuppressive Plasmocytes that Interfere with T-Cell-Dependent Immunogenic Chemotherapy in Prostate Cancer
As prostate cancer cells adapt to lower..
Michael Schweizer, MD:
University of Washington
Peter Nelson, MD
Bipolar Androgen Therapy (BAT): Molecular Drivers of Response and Resistance
Supplementing a patient’s immune response by engineering..
Saul Priceman, PhD:
City of Hope National Medical Center
Stephen Forman, MD
Targeting Metastatic Prostate Cancer with PSA-Specific Chimeric Antigen Receptor-Engineered T-Cells
New hormonal treatments for prostate cancer such..
Sean McGuire, MD, PhD:
Baylor College of Medicine
Bert O’Malley, MD
Targeting the Mitochondrial Pyruvate Carrier in Castration- Resistant Prostate Cancer
Immune checkpoint inhibitors “take the brakes” off..
Ravi Madan, MD:
James Gulley, MD, PhD
Using A Therapeutic Cancer Vaccine to Enhance Anti-PD-1 Therapy Prior to Prostatectomy
While most men with prostate cancer initially..
Zhenfei Li, PhD:
Cleveland Clinic Foundation
Nima Sharifi, MD; Eric Klein, MD
A Novel Abiraterone Metabolite as a Predictive Biomarker for Clinical Response to Abiraterone
A highly aggressive subtype of treatment-resistant prostate..
John Kyung Lee, MD:
University of California, Los Angeles
Owen Witte, MD
Therapeutic Targeting of N-Myc-Driven Human Small Cell Neuroendocrine Prostate Cancer
New therapeutic targets and prognostic biomarkers for..
Vishal Kothari, PhD:
Arul Chinnaiyan, MD, PhD; Felix Feng, MD
Investigating DNAPK as a Therapeutic Target and a Prognostic Biomarker in Castration-Resistant Prostate Cancer
The emergence of treatment-resistant prostate cancer (CRPC)..
Won Kim, MD:
University of California, San Francisco
Charles Ryan, MD; Eric Small, MD
Dissecting Variant Androgen Signaling Phenotypes to Guide Treatment Selection in Abiraterone Acetate and Enzalutamide-Resistant Prostate Cancer
Metabolic oxidative phosphorylation (OXPHOS) is a biochemical..
Joseph Ippolito, MD, PhD:
Washington University School of Medicine in St. Louis
Jeffrey Arbeit, MD; Farrokh Dehdashti, MD
Characterizing and Imaging Metabolic Symbiosis in Castrate- Resistant Prostate Cancer
Long noncoding RNAs (lncRNAs) play a critical..
Amanda Hargrove, PhD:
Hashim Al-Hashimi, PhD; Peter Dervan, PhD
Targeting the lncRNA SChLAP1 in Aggressive Prostate Cancer by the Assembly of Multivalent Small Molecule Inhibitor
Men with progressive metastatic prostate cancer are..
Justin Drake, PhD:
Rutgers University Cancer Institute of New Jersey
Robert DiPaola, MD
Elucidating Kinase Activation Pathways in Advanced Prostate Cancer
Although family history is well-established as a..
Heather Cheng, MD, PhD:
Identifying High-Penetrance Prostate Cancer Risk Genes: Leveraging Families for Next Generation Discovery and Prevention
The development of androgen axis inhibitors Zytiga®..
Rahul Aggarwal, MD:
Eric Small, MD
Targeting MYC-Driven Cell Cycle Progression in Neuroendocrine Prostate Cancer with Gallium Citrate PET as a Novel Biomarker of MYC Transcriptional Activity
Genomic profiling of primary and metastatic treatment-resistant..
Wassim Abida, MD, PhD:
Memorial Sloan Kettering Cancer Center
Howard Scher, MD; Charles Sawyers, MD
Investigating Treatment Selection and Resistance Using Prostate Cancer Genomics